Literature DB >> 27489526

The Present and Future of Inflammatory Bowel Disease Treatment.

William J Sandborn1.   

Abstract

Year:  2016        PMID： 27489526      PMCID： PMC4969780     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

Review 1.  The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.

Authors:  Reena Khanna; Nilesh Chande; Séverine Vermeire; William J Sandborn; Claire E Parker; Brian G Feagan
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

2.  Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.

Authors:  William J Sandborn; Jean-Frédéric Colombel; Subrata Ghosh; Bruce E Sands; Gerald Dryden; Xavier Hébuterne; Rupert W Leong; Brian Bressler; Thomas Ullman; Peter L Lakatos; Walter Reinisch; Li-An Xu; Allison Luo
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

3.  Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Authors:  William J Sandborn; Brian G Feagan; Douglas C Wolf; Geert D'Haens; Severine Vermeire; Stephen B Hanauer; Subrata Ghosh; Heather Smith; Matthew Cravets; Paul A Frohna; Richard Aranda; Sheila Gujrathi; Allan Olson
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

Review 4.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; Siddharth Singh; Niels V Casteele; Brigid S Boland; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 5.  Integrin-based therapeutics: biological basis, clinical use and new drugs.

Authors:  Klaus Ley; Jesus Rivera-Nieves; William J Sandborn; Sanford Shattil
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

6.  Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.

Authors:  W J Sandborn; B R Bhandari; R Fogel; J Onken; E Yen; X Zhao; Z Jiang; D Ge; Y Xin; Z Ye; D French; J A Silverman; B Kanwar; G M Subramanian; J G McHutchison; S D Lee; L M Shackelton; R K Pai; B G Levesque; B G Feagan
Journal:  Aliment Pharmacol Ther       Date:  2016-05-24       Impact factor: 8.171
  6 in total
  12 in total

Review 1.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 2.  Frontiers in Drug Research and Development for Inflammatory Bowel Disease.

Authors:  Diego Currò; Daniela Pugliese; Alessandro Armuzzi
Journal:  Front Pharmacol       Date:  2017-06-23       Impact factor: 5.810

Review 3.  Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.

Authors:  Prashanth Rawla; Tagore Sunkara; Jeffrey Pradeep Raj
Journal:  J Inflamm Res       Date:  2018-05-16

4.  Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.

Authors:  Ulf Helwig; Michael Mross; Stefan Schubert; Heinz Hartmann; Alina Brandes; Dara Stein; Christian Kempf; Jana Knop; Sarah Campbell-Hill; Robert Ehehalt
Journal:  BMC Gastroenterol       Date:  2020-07-08       Impact factor: 3.067

Review 5.  Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease.

Authors:  Martin Maronek; Rene Link; Lubos Ambro; Roman Gardlik
Journal:  Cells       Date:  2020-04-18       Impact factor: 6.600

6.  Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis.

Authors:  Ho Pan Sham; Mark Bazett; Momir Bosiljcic; Hyungjun Yang; Beryl Luk; Hong T Law; Vijay Morampudi; Hong B Yu; Jim Pankovich; Simon Sutcliffe; Brian Bressler; John K Marshall; Richard N Fedorak; Jenny Chen; Michelle Jones; Hal Gunn; Shirin Kalyan; Bruce A Vallance
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

7.  The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.

Authors:  Linda Russi; Michael Scharl; Gerhard Rogler; Luc Biedermann
Journal:  Inflamm Intest Dis       Date:  2017-10-19

Review 8.  Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.

Authors:  Parakkal Deepak; Edward V Loftus
Journal:  Drug Des Devel Ther       Date:  2016-11-11       Impact factor: 4.162

9.  Biologic treatment of Japanese patients with inflammatory bowel disease.

Authors:  Jörg Mahlich; Katsuyoshi Matsuoka; Rosarin Sruamsiri
Journal:  BMC Gastroenterol       Date:  2018-11-01       Impact factor: 3.067

10.  Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study.

Authors:  Clarissa Allner; Michaela Melde; Emily Becker; Friederike Fuchs; Laura Mühl; Entcho Klenske; Lisa Müller; Nadine Morgenstern; Konstantin Fietkau; Simon Hirschmann; Raja Atreya; Imke Atreya; Markus F Neurath; Sebastian Zundler
Journal:  BMC Gastroenterol       Date:  2020-04-15       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.